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Háttér – A Charcot–Marie–Tooth (CMT) -betegség 1-es
típusának hátterében többek között a PMP22 és az EGR2
gének mutációi és kópiaszám-változásai is állhatnak. A
„Hereditary Neuropathy with Liability to Pressure Palsy”
(nyomásos bénulásokra hajlamosító örökletes neuropathia,
HNPP) oka a PMP22 gén deléciója. A PMP22 gén dupliká-
ciójának és más, CMT-t okozó gének mutációinak kapcso-
latáról több irodalomban is találhatunk utalást. Ezekben az
esetekben az egyes családtagok eltérô klinikai képe hívhatja
fel a figyelmet a módosító gének lehetséges szerepére. A
PMP22 és az EGR2 gének közötti interakciók még nem
tisztázottak teljesen.
Esetbemutatás – Férfi testvérpárt mutatunk be, akiknek az
EGR2 gén c. 1142 G>A (Arg381His) heterozigóta patogén
mutációja következtében kései kezdetû CMT1 betegség
alakult ki. Az idôsebb testvérnek enyhébb tünetei vannak, a
patogén mutáción kívül még PMP22 deléciót is azonosítot-
tunk nála. 
Megbeszélés – A két patológiás eltérés együttes jelenléte
nem súlyosbította a klinikai képet. A PMP22 deléciónak
ebben az esetben inkább jótékony módosító hatását találtuk,
mely a PMP22 és az EGR2 gének közötti interakcióra utal. A
PMP22 deléció növelheti a Schwann-sejtek proliferációját,
így kompenzálhatja az EGR2 gén c. 1142 G>A (Arg381His)
patogén mutációjának negatív hatását.
Kulcsszavak: CMT, EGR2 génmutáció, PMP22 deléció, 
gén-gén interakció, együttes jelenlét
Background – Mutations of both the PMP22 and EGR2
genes cause Charcot-Marie-Tooth (CMT) disease type 1.
Deletion of the PMP22 gene, results in hereditary neuropa-
thy with liability to pressure palsies. More publications exist
about the interaction of PMP22 duplication and other CMT-
causing gene mutations. In these cases the intrafamiliar dis-
cordant phenotypes draw the attention to the possible role of
modifying genes. The gene-gene interactions between the
PMP22 and EGR2 genes are not well understood. 
Case report – We report two brothers with late onset CMT1
due to a c. 1142 G>A (Arg381His) heterozygous substitu-
tion in the EGR2 gene. Additionally, the older brother with
the less severe symptoms harbored the PMP22 gene deletion
also. 
Conclusion – The coexistence of the two genetic alterations
did not aggravate the clinical symptoms. Moreover, the
PMP22 deletion appeared to have a beneficial modifying
effect, thus implying potential gene-gene interaction of
PMP22 and EGR2. PMP22 deletion may increase Schwann
cells proliferation and compensate the dominant-negative
effect of the Arg381His substitution in the EGR2 gene.
Keywords: CMT, EGR2 gene mutation, PMP22 deletion,
gene-gene interaction, coexistence
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Charcot-Marie-Tooth disease (CMT) is a geneti-cally heterogeneous group of hereditary motor
and sensory neuropathies. Its estimated prevalence
is 1:25001. Charcot-Marie-Tooth disease is charac-
terized by the degeneration or abnormal develop-
ment of peripheral nerves and is transmitted with
different genetic patterns2. More than 40 different
CMT genes and over 50 loci have been identified
so far (www.molgen.ua.ac.be/CMTMutations)3.
CMT can be divided into major clinical categories,
and can further be classified into different subtypes
according to the underlying genetic alterations.
Harding and Thomas have separated the type 1 and
type 2 of CMT based on motor nerve conduction
velocity4. CMT type 1 primarily affects the myelin
sheath and can either be inherited in a dominant,
recessive or X-linked (CMT1, CMT3, and CMT4)
manner. CMT type 2 primarily affects axons and is
either dominant or recessive. 
Defects in the Peripheral Myelin Protein-22
(PMP22), Gap Junction Protein (GJB1), Myelin
Protein Zero (MPZ), and Mitofusin 2 (MFN2) genes
are the most common genetic causes of hereditary
peripheral neuropathies5. About 70% of CMT1A
(MIM#118220) is caused by a 1.5 Mb tandem
duplication of the PMP22 gene which is located in
the 17p11.2-p12 chromosomal region6. Unequal
crossing over between two highly homologous
repeats on chromosome 17p12 can either cause
duplication or deletion of the given chromosomal
region, resulting in three copies or only one copy of
the PMP22 gene and thus giving rise to CMT1A or
hereditary neuropathy with liability to pressure
palsies (HNPP) (MIM#162500), respectively7. The
phenotypic variability is large, duplication or point
mutation of the PMP22 gene may cause not only
CMT1A, but Dejerine-Sottas neuropathy (DSN)
(MIM#145900), congenital hypomyelinating neu-
ropathy (CHN) (MIM#605253) or Roussy-Lévy
syndrome (MIM#180800) also8–10. Genetic defects
of the EGR2 can lead to CMT1D (MIM#607678),
Dejerine-Sottas neuropathy or congenital hypo -
myelinating neuropathy. The EGR2 gene encodes a
transcription factor regulating myelination of
peripheral and cranial nerves and activating tran-
scription of myelin genes, including GJB1, PMP22,
MPZ and PRX (periaxin)11. The EGR2 mutations in
CMT are generally associated with severe forms of
demyelination or dysmyelination.
Disease severity can be highly variable, even
among probands with identical mutations even
within the same kinship. Although stochastic effects
and environmental factors are likely to contribute
to phenotype variability12, anecdotal reports from
the literature13 suggest that mutations in other CMT
genes can modify the CMT1A phenotype caused by
PMP22 duplication. Here we report the clinical fea-
tures of two members of a Hungarian family with
CMT due to heterozygous missense EGR2 mutation
apparently modified by PMP22 gene deletion.
Patients and methods
Here we report the case of two brothers, aged 45
and 49 years. The patients gave written informed
consent. This study was carried out according to the
Helsinki Declaration of 1975. This study was
approved by local ethics committee. Neurophy -
siological investigations were performed by stan-
dard techniques (Dantec Keypoint, Denmark).
Nerve conduction studies were assessed for the
median, ulnar, tibial and sural nerves. Motor nerve
conduction velocity (MCV), distal motor latency
(DL) and compound muscle action potential
(CMAP) were recorded for the median, ulnar and
tibial nerves. Sensory nerve conduction velocity
(SCV) and sensory nerve action potential (SNAP)
were assessed for the median and sural nerves.
Sural nerve biopsy was performed and light and
electron microscopy preparations were performed
according to standard methods. Blood samples were
collected for molecular analysis. PMP22 gene dele-
tion and duplication was detected by MLPA
(Multiplex Ligation-dependent Probe Amplifi -
cation) was performed using the SALSA MLPA
KIT P033-B2 CMT1 (MRC-Holland, Amsterdam,
The Netherlands) according to the manufacturer’s
introduction14 and confirmed by real-time PCR
(ABI 7300)15. All coding exons of GJB1, MPZ and
EGR2 genes have been investigated. The PCR prod-
ucts were sequenced using the ABI Prism 3500
sequencing machine. The received sequences were
compared with the human reference genome
(NM_000399.3; NM_000530.6; NM_000166)
using the NCBI Blast program. The effect of the
detected mutation was analyzed by the PolyPhen-2
prediction software.
Results
CLINICAL PROFILE
Patient 1: The first symptoms of the 45 years old
patient appeared at the age of 25. First investiga-
tions revealed pes cavus with distal type muscle
atrophy and paresis. Mild mitral valve insufficiency
was also reported in the patients’ history. Clinical
investigation at age 45 revealed mild-moderate
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atrophy and weakness predominantly in the distal
muscles of the upper limb with very severe atrophy
and weakness in the lower limb muscles. He was
wheelchair-bound, only a minimal extension of the
lower limb could be achieved from a semi-flexed
position. Fasciculation could be observed in his
shoulder and arm muscles. His deep tendon reflex-
es were absent. Sensation of pain and light touch
was decreased below the wrist and knee joints bilat-
erally. Proprioceptive sensation including joint
position and vibration were impaired below the lev-
els of the ankles.
Patient 2: The first symptoms of the 49-year-old
brother started at age 24 with distal type muscle
atrophy and weakness in the lower extremities.
Over the years the patient suffered from multiple
diseases and was treated for cataracts, diabetes mel-
litus, gout and hypertension. He had no clinical his-
tory suggestive of liability to pressure palsies.
Neurological examination at the age of 49 revealed
pes cavus, atrophy and severe weakness mainly in
the distal muscles of the lower extremities, absent
deep tendon reflexes, severe sensory deficiency was
observed to all sensory modalities below the wrist
and knee joints (Table 1.). He is still ambulatory
with crutches. The father of the siblings also suf-
fered from similar symptoms, however he refused
the offered neurological examination and genetic
tests. The mother did not have any neurological
symptoms.
NERVE CONDUCTION STUDIES
In case of Patient 1 neurophysiology could not
detect any peroneal and sural nerve response. Motor
nerve conduction velocities of the median and ulnar
nerve were moderately and severely decreased,
respectively. Distal latencies were increased. The
amplitudes of the motor response were slightly
decreased. In Patient 2 ENG could not detect a sural
nerve response. The peroneal nerve motor response
could be detected only at the ankle with very low
amplitude. The motor conduction velocities of the
median and ulnar nerves were decreased. Ampli -
tudes of motor responses were slightly decreased
(Table 2.). 
Table 1. The clinical data of the two investigated patients
Patients Patient 1 Patient 2
Age/Onset 47/25 51/24
Concomittant diseases Mitral valve insuffiency Diabetes mellitus, hypertension, cataract
Muscle atrophy and weakness Moderate atrophy and paresis in the Moderate atrophy and paresis in the 
upper, severe in the lower limbs limbs. Only the distal muscles of the 
lower limbs were severely affected
Reflexes Absent tendon reflexes Absent tendon reflexes
ENG Severe demyelinating neuropathy. Severe demyelinating neuropathy 
No peroneal and sural response predominantly in the lower limbs
were detected
Sural nerve biopsy Segmental demyelinisation with Not done
increased peri-, and endoneural 
connective tissue
Genetic results PMP22: norm EGR2: c.1142 G>A PMP22: deletion EGR2: c.1142 G>A 
(p.Arg381His) mutation (p.Arg381His) mutation
Barin CT Not done Lacunar infarcts in the basal ganglia
Table 2. The nerve conduction study data of the two patients
Patients Patient 1 Patient 2
DL (ms) Amp (mV) CV (m/s) DL (ms) Amp (mV) CV (m/s)
Right median nerve motor 5.9 4.6 36.3 5.8 4.8 37.6
Right ulnar nerve motor 4.9 4.5 31.2 5.3 4.2 38.0
Right peroneal nerve motor absent absent absent 14.3 0.2 absent
Right sural nerve absent absent absent absent absent absent
Amp: Amplitude; NCV: Nerve Conduction Velocity; DL: Distal Latency
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SURAL NERVE BIOPSY
Sural nerve biopsy was taken only from Patient 1
(only with EGR2 mutation). In his sural nerve seg-
mental demyelination, increased peri- and endo -
neural connective tissue could be seen. Semithin
cross-sections of the nerve showed a mild reduction
of myelinated and unmyelinated fiber density.
Myelin degradation products could be observed fre-
quently. Some fibers had thin myelin sheaths. The
number of dystrophic axons and small fibers result-
ing from axonal degeneration and regeneration
were increased. Onion bulb formation was rare
(Figure 1.). In Patient 2 (with both EGR2 and
PMP22 alterations) sural nerve biopsy was not per-
formed.
MOLECULAR GENETIC RESULTS
Genetic analyses revealed the c. 1142 G>A
(Arg381His) mutation in the exon 4 of the EGR2
gene in both patients in heterozygous form. The
PolyPhen-2 software predicted this substitution as
probably damaging (PSIC score: 0,986). This muta-
tion has previously been reported by Pareyson et al.
(Arg381His) also as pathogenic mutation16. Genetic
testing of the PMP22 gene detected a deletion in
Patient 2. The PMP22 deletion could not be identi-
fied in the other sibling. No pathogenic alteration
was found in the GJB1 and MPZ genes of our
patients. 
Discussion
This study reports the coexistence of the PMP22
deletion and EGR2 mutation. Based on the pheno-
type this gene-gene interaction did not have a dele-
terious effect, since the patient harboring both
mutations had a less severe phenotype than his
younger brother despite his concomitant diseases
(diabetes mellitus) also affecting peripheral nerves.
However we can not exclude the effect of environ-
mental factors, although the two brothers have been
living in the same household. The discordant phe-
notype of the brothers suggests the modifying effect
of PMP22 deletion. As far as we know only one
case report has been published concerning the coex-
istence of a PMP22 deletion and the defect of
another gene in CMT patient17. In this case the
coexistence of the ABCD1 gene mutation (which
results in adrenoleukodystrophy or adrenomye -
loneuropathy, but not in CMT) aggravated the clin-
ical symptoms due to PMP22 deletion. More publi-
cations exist about the interaction of PMP22
duplication and other CMT-causing gene muta-
tions13, 17. In these cases the intrafamiliar discordant
phenotypes draw the attention to the possible role
of modifying genes. In a Dutch report, the interac-
tion of the PMP22 duplication and the G112S and
I92V mutations of the LITAF gene resulted in a very
severe phenotype13. In another family, two brothers
had PMP22 gene duplication on one allele, which
they inherited from their father, on the other allele
the missense mutation Arg200Gly of the GJB1
gene, which they inherited from their mother17. The
younger brother had Dejerine-Sottas syndrome
resulting in severe kyphoscoliosis causing respira-
tory compromise and death at an early age. The
older brother with the same genotype had less
severe clinical manifestations. This observation
suggests that unknown environmental or other sto-
chastic factors may play a role in the clinical
expression and progression of this genetically deter-
mined disease. This assumption is supported by the
different clinical picture of two pairs of homozy-
gotic twins with CMT1A due to PMP22 duplica-
tion12. In both families the less-affected twin had a
greater degree of palpable nerve enlargement, sug-
gesting either a protective effect of interstitial nerve
hypertrophy on axon function or, alternatively, that
hypertrophy may have reflected a better ability to
Figure 1. The sural nerve biopsy of Patient 1 examina-
ted by light microscopy. A mild reduction of myelinated
and unmyelinated fibers can be observed. (Paraphenyl -
enediamine staining, × 400)
Marking: Arrowhead: fibers with thin myelin; Arrow: tomacoulos
fibers; Asterisk: small regeneration axon groups
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restore lost function through mechanisms such as
remyelination. The low prevalence of PMP22
duplication has been associated by genetic and /or
epigenetic modifying factors as well18. These cases
suggest that the coexistence of different gene vari-
ances, and/ or epigenetic and environmental factors
can be additive in their effects on the clinical phe-
notypes. 
The Early Growth Response protein 2 (EGR2) is
a zinc finger transcription factor. It induces expres-
sion of several proteins involved in myelin sheath
formation and maintenance. It is activated in
Schwann cells before the onset of myelination.
EGR2 activates the transcription of several myelin-
associated genes, such as PMP22, Cx32 (GJ1B) and
PRX19. The disease causing Arg381His (R381H)
EGR2 substitution has previously been described in
families both with early and late onset CMT and
congenital hypomyelinating neuropathy16, 20. In one
family with early onset CMT one of the patients
showed a unique combination of clinically overt
cranial nerve deficits16. In our cases cranial nerve
involvement was not detected. The Arg381His
(R381H) substitution of EGR2 is localized within
the alfa-helix of the second zinc finger. The DNA
binding sites of the EGR2 transcription factor are
connected to the zinc finger domains and it inter-
acts with the DNA at the consensus EGR2 binding
site21. When the transcription factor binds with the
DNA the arginine is able to form hydrogen bonds
on the G rich strand on the consensus binding site.
If the arginine is mutated to histidine, the hydrogen
bonds will not be established. 
The coexistence of an EGR2 mutation and anoth-
er pathogenic Charcot-Marie-Tooth -causing muta-
tion (GJB1) has been reported in a family, where
the R359W mutation in EGR2 was shared by the
affected daughter and her father22. The daughter
also had a V136A de novo mutation in the GJB1
gene. The father, harboring only the EGR2 muta-
tion, showed a mild CMT phenotype, however his
daughter with the coexisting mutations had a more
severe phenotype. 
The pathogenic mutation detected in our patients
is located within the DNA binding domain (DBD)
of the EGR2 gene and results in absent DNA bind-
ing and transcriptional activity. Nagarajan et al dis-
cussed the effect of this mutation as a dominant-
negativ inhibition of the EGR2-mediated ex p res -
 sion of these essential myelin proteins23 leading to
demyelination. PMP22 is involved in controlling
myelin thickness and stability24 and PMP22 defi-
ciency can increase proliferation of Schwann cells
and fibroblast cultures in vitro resulting in axons
with abnormally thick myelin (tomacula forma-
tion). The tomaculas are formed by excessive
myelin folding, which is not compacted25. With
these biochemical processes we would suppose a
much worse condition for Patient 2. However the
coexisting PMP22 gene deletion can be one of the
other genetic factors to compensate the effect of the
deleterious EGR2 mutation. 
In conclusion: this is the first report describing
the coexistence of PMP22 gene deletion and a path-
ogenic mutation of the EGR2 gene causing
CMT1A. The coexistence of the PMP22 deletion
and EGR2 mutation did not aggravate the clinical
symptoms, since the patient with the double genetic
defects had less severe phenotype. Our observation
suggests the importance of further investigation of
the gene-gene interaction in monogenic disorders
such as Charcot-Marie-Tooth 1A for a better under-
standing of phenotype-genotype correlations. 
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